Instruction Manual

Parainfluenza 1, 2 & 3 IgM ELISA

Cat. No.: 07I-546202

Enzyme immunoassay
for the detection and quantitative determination
of human IgM antibodies against Parainfluenza 1, 2 & 3
in serum and plasma

Storage: 4-8°C

May 2002

ICN Diagnostics

<table>
<thead>
<tr>
<th></th>
<th>Belgium</th>
<th>France</th>
<th>Germany</th>
<th>Italy</th>
<th>The Netherlands</th>
<th>United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phone:</td>
<td>02-466.00.00</td>
<td>0800-130.373</td>
<td>0800-426.67.337</td>
<td>800-011.643</td>
<td>0800-022.7416</td>
<td>0800-282.474</td>
</tr>
<tr>
<td>Fax:</td>
<td>02-466.26.42</td>
<td>01-60.19.34.60</td>
<td>0800-629.67.337</td>
<td>800-225.220</td>
<td>0800-022.7489</td>
<td>0800-614.735</td>
</tr>
</tbody>
</table>

Free Phone Western Europe: 00800-7777.9999
Free Phone Western Europe: 00800-6666.8888
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Intended Use</td>
<td>3</td>
</tr>
<tr>
<td>2. General Information</td>
<td>3</td>
</tr>
<tr>
<td>3. Principle of the Test</td>
<td>3</td>
</tr>
<tr>
<td>4. Limitations, Precautions and General Comments</td>
<td>4</td>
</tr>
<tr>
<td>5. Reagents Provided</td>
<td>4</td>
</tr>
<tr>
<td>6. Materials Required but not Provided</td>
<td>5</td>
</tr>
<tr>
<td>7. Specimen Collection and Handling</td>
<td>5</td>
</tr>
<tr>
<td>8. Assay Procedure</td>
<td>6</td>
</tr>
<tr>
<td>9. Evaluation</td>
<td>6</td>
</tr>
<tr>
<td>10. Assay Performance</td>
<td>7</td>
</tr>
<tr>
<td>11. References</td>
<td>7</td>
</tr>
<tr>
<td>12. Ordering Information</td>
<td>8</td>
</tr>
</tbody>
</table>
1. Intended Use

The ICN Parainfluenza 1, 2 & 3 IgM antibody ELISA kit has been designed for the detection and the quantitative determination of specific IgM antibodies against Parainfluenza 1, 2 & 3 in serum and plasma. Further applications in other body fluids are possible and can be requested from the Technical Service of ICN.

This assay is intended for in-vitro diagnostic use only.

Laboratory results can never be the only base of a medical report. The patient history and further tests have additionally to be taken into account.

2. General Information

The infection with parainfluenza viruses is air-borne from man-to-man. Various species of animals may serve as virus reservoir. Parainfluenza viruses are endemically spread worldwide. The seroprevalence of parainfluenza in infants in their first year of life is 50%. Typical for parainfluenza viruses are frequent reinfections, this applies particularly to parainfluenza 3 viruses. Incubation time is 2-6 days.

The parainfluenza viruses are a subgroup of the paramyxoviruses. They are of the same size of approximately 150 – 300 nm. They are ether-sensitive, agglutinate human or chicken erythrocytes and have a receptor-destructive enzyme, as known from influenza viruses. They can be cultivated best in primary monkey cell cultures or in human epithel cell cultures, however, less successful in embryonized chicken eggs. It is differentiated between parainfluenza 1, 2, 3 and 4.

Together with the respiratory syncytial viruses (RS viruses), the pathogens belong to the major viral pathogens of diseases of the respiratory tract, accompanied by severe clinical symptoms. In adults, parainfluenza virus causes a feverish rhinitis and laryngitis. First signs are sudden headaches, pain in muscles and joints, followed by fever of 38-39°C. If the lower respiratory tract is involved, additionally trachyphonea and dry cough develops as a sign of tracheobronchitis.

Parainfluenza 1 causes severe pneumonias in newborns, manifested by high fever, cyanosis, dyspnœa and bloody purulent sputum. Sometimes meningitis symptoms occur at the same time.

Parainfluenza 2 very often causes an acute laryngotracheobronchitis with pseudocroup in infants and children. First signs of the infection are catarrhal symptoms, followed by trachyphoena, dry barking cough and inspiratory stridor.

Parainfluenza 3 viruses are considered the major pathogens of pneumonia and bronchiolitis.

While types 1, 2 and 3 are distributed worldwide, parainfluenza type 4 appears only in the USA. Infections 1 and 3 occur all the year, while parainfluenza 2 and 4 viruses appear only sporadically.

Laboratory diagnosis of parainfluenza viruses is done with haemagglutination inhibiting test (HIT) complement binding reaction (CF) and neutralisation test (NT). Newer methods are IFA and ELISA, which allow to identify IgA, IgG and IgM antibodies in the patient serum. In differential diagnosis, tests for other paramyxoviruses like mumps, shipping fever viruses and simianvirus type 5 have to be performed due to possible cross-reactions.
3. Principle of the Test

The ICN Parainfluenza 1, 2 & 3 IgM antibody test kit is based on the principle of the enzyme immunoassay (EIA). Parainfluenza 1, 2 & 3 antigen is bound on the surface of the microtiter strips. Diluted patient serum or ready-to-use standards are pipetted into the wells of the microtiter plate. A binding between the IgM antibodies of the serum and the immobilized Parainfluenza 1, 2 & 3 antigen takes place. After a one hour incubation at room temperature, the plate is rinsed with diluted wash solution, in order to remove unbound material. Then ready-to-use anti-human-IgM peroxidase conjugate is added and incubated for 30 minutes. After a further washing step, the substrate (TMB) solution is pipetted and incubated for 20 minutes, inducing the development of a blue dye in the wells. The color development is terminated by the addition of a stop solution, which changes the color from blue to yellow. The resulting dye is measured spectrophotometrically at the wavelength of 450 nm. The concentration of the IgM antibodies is directly proportional to the intensity of the color.

4. Limitations, Precautions and General Comments

• Only for in-vitro use! Do not ingest or swallow! The usual laboratory safety precautions as well as the prohibition of eating, drinking and smoking in the lab have to be followed.
• All sera and plasma or buffers based upon, have been tested respective to HBsAg, HIV and HCV with recognized methods and were found negative. Nevertheless precautions like the use of latex gloves have to be taken.
• Serum and reagent spills have to be wiped off with a disinfecting solution (e.g. sodium hypochlorite, 5%) and have to be disposed of properly.
• All reagents have to be brought to room temperature (18 to 25°C) before performing the test.
• Before pipetting all reagents should be mixed thoroughly by gentle tilting or swinging. Vigorous shaking with formation of foam should be avoided.
• It is important to pipet with constant intervals, so that all the wells of the microtiter plate have the same conditions.
• When removing reagents out of the bottles, care has to be taken that the stoppers are not contaminated. Further a possible mix-up has to be avoided. The content of the bottles is usually sensitive to oxidation, so that they should be opened only for a short time.
• In order to avoid a carry-over or a cross-contamination, separate disposable pipet tips have to be used.
• No reagents from different kit lots have to be used, and they should not be mixed with one another.
• All reagents have to be used within the expiry period.
• In accordance with a Good Laboratory Practice (GLP) or following ISO9001 all laboratory devices employed should be regularly checked regarding the accuracy and precision. This refers amongst others to microliter pipets and washing or reading (ELISA-Reader) instrumentation.
• The contact of certain reagents, above all the stopping solution and the substrate with skin, eye and mucosa has to be avoided, because possible irritations and acid burns could arise, and there exists a danger of intoxication.
5. Reagents Provided

The kit contains sufficient reagents for 12 x 8 = 96 determinations. The strips and solutions have to be stored at 4-8 °C. The expiry date is mentioned on the labels.

<table>
<thead>
<tr>
<th>Components</th>
<th>Volume / Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parainfluenza 1, 2 &amp; 3 antigen coated microtiter strips</td>
<td>12</td>
</tr>
<tr>
<td>Negative Control</td>
<td>2 mL</td>
</tr>
<tr>
<td>Cut-Off Standard</td>
<td>2 mL</td>
</tr>
<tr>
<td>Weak Positive Control</td>
<td>2 mL</td>
</tr>
<tr>
<td>Positive Control</td>
<td>2 mL</td>
</tr>
<tr>
<td>Enzyme Conjugate</td>
<td>12 mL</td>
</tr>
<tr>
<td>Substrate</td>
<td>12 mL</td>
</tr>
<tr>
<td>Stop Solution</td>
<td>12 mL</td>
</tr>
<tr>
<td>Sample Diluent</td>
<td>60 mL</td>
</tr>
<tr>
<td>Washing Buffer (10×)</td>
<td>60 mL</td>
</tr>
<tr>
<td>Plastic foils</td>
<td>2</td>
</tr>
<tr>
<td>Plastic bag</td>
<td>1</td>
</tr>
</tbody>
</table>

5.1. Mikrotiter Strips
12 strips with 8 breakable wells each, coated with a Parainfluenza 1, 2 & 3 antigen. Ready-to-use.

5.2. Negative Control
2 mL, protein solution diluted with PBS, contains no IgM antibodies against Parainfluenza 1, 2 & 3. Addition of 0.02 % methylisothiazolone and 0.02 % bromonitrodioxane. Ready-to-use.

5.3. Cut-Off Standard
2 mL human serum diluted with PBS, contains a low concentration of IgM antibodies against Parainfluenza 1, 2 & 3. Addition of 0.02 % methylisothiazolone and 0.02 % bromonitrodioxane. Ready-to-use.

5.4. Weak Positive Control
2 mL, human serum diluted with PBS, contains a medium concentration of IgM antibodies against Parainfluenza 1, 2 & 3. Addition of 0.02 % methylisothiazolone and 0.02 % bromonitrodioxane. Ready-to-use.

5.5. Positive Control
2 mL, human serum diluted with PBS, contains a high concentration of IgM antibodies against Parainfluenza 1, 2 & 3. Addition of 0.02 % methylisothiazolone and 0.02 % bromonitrodioxane. Ready-to-use.

5.6. Enzyme Conjugate
12 mL, anti-human-IgM-HRP, in protein-containing buffer solution. Addition of 0.02 % methylisothiazolone and 0.02 % bromonitrodioxane. Ready-to-use.

5.7. Substrate
12 mL, TMB (tetramethylbenzidin). Ready-to-use.

5.8. Stop Solution
12 mL, 0.5 M sulfuric acid. Ready-to-use.

5.9. Sample Diluent
60 mL, PBS/BSA buffer. Addition of 0.1 % sodium azide. Ready-to-use.

5.10. Washing Buffer
60 mL, PBS + Tween 20, 10x concentrate. Final concentration: dilute 1+9 with distilled water. If during the cold storage crystals precipitate, the concentrate should be warmed up at 37°C for 15 minutes.
5.11. Plastic Foils
2 pieces to cover the microtiter strips during the incubation.

5.12. Plastic Bag
Resealable, for the dry storage of non-used strips.

6. Materials Required but not Provided
- 5 µL-, 100 µL- and 500 µL micro- and multichannel pipets
- Microtiter Plate Reader (450 nm)
- Microtiter Plate Washer
- Reagent tubes for the serum dilution
- Bidistilled water

7. Specimen Collection and Handling
Principally serum or plasma (EDTA, heparin) can be used for the determination. Serum is separated from the blood, which is aseptically drawn by venipuncture, after clotting and centrifugation. The serum or plasma samples can be stored refrigerated (4-8°C) for up to 48 hours, for a longer storage they should be kept at - 20°C. The samples should not be frozen and thawed repeatedly. Lipemic, hemolytic or bacterially contaminated samples can cause false positive or false negative results.

For the performance of the test the samples (not the standards) have to be diluted 1:101 with ready-to-use sample diluent (e.g. 5 µL serum + 500 µL sample diluent).

8. Assay Procedure

8.1. Preparation of Reagents

**Washing Solution:** dilute before use 1+9 with distilled water. If during the cold storage crystals precipitate, the concentrate should be warmed up at 37°C for 15 minutes.
- Strict adherence to the protocol is advised for reliable performance. Any changes or modifications are the responsibility of the user.
- All reagents and samples must be brought to room temperature before use, but should not be left at this temperature longer than necessary.
- Standards and samples should be assayed in duplicate.
- A standard curve should be established with each assay.
- Return the unused microtiter strips to the plastic bag and store them dry at 4-8°C.

8.2. Assay Steps
1. Prepare a sufficient amount of microtiter wells for the standards, controls and samples in duplicate as well as for a substrate blank.
2. Pipet 100 µL each of the **diluted** (1:101) samples and the **ready-to-use** standards and controls respectively into the wells. Leave one well empty for the substrate blank.
3. Cover plate with the enclosed foil and incubate at room temperature for 60 minutes.
4. Empty the wells of the plate (dump or aspirate) and add 300 µL of diluted washing solution. This procedure is repeated totally three times. Rests of the washing buffer are afterwards removed by gentle tapping of the microtiter plate on a tissue cloth.
5. Pipet 100 µL each of ready-to-use conjugate into the wells. Leave one well empty for the substrate blank.
6. Cover plate with the enclosed foil and incubate at room temperature for 30 minutes.
7. Empty the wells of the plate (dump or aspirate) and add 300 µL of diluted washing solution. This procedure is repeated totally three times. Rests of the washing buffer are afterwards removed by gentle tapping of the microtiter plate on a tissue cloth.
8. Pipet 100 µL each of the ready-to-use substrate into the wells. This time also the substrate blank is pipetted.
9. Cover plate with the enclosed foil and incubate at room temperature for 20 minutes in the dark (e.g. drawer).
10. To terminate the substrate reaction, pipet 100 µL each of the ready-to-use stop solution into the wells. Pipet also the substrate blank.
11. After thorough mixing and wiping the bottom of the plate, perform the reading of the absorption at 450 nm (optionally reference wavelength of 620 nm). The color is stable for at least 60 minutes.

9. Evaluation

The mean values for the measured absorptions are calculated after subtraction of the substrate blank value. The difference between the single values should not exceed 10 %.

Example

<table>
<thead>
<tr>
<th></th>
<th>OD Value</th>
<th>corrected OD</th>
<th>Mean OD Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Substrate Blank</td>
<td>0.016</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative Control</td>
<td>0.032 / 0.034</td>
<td>0.016 / 0.018</td>
<td>0.017</td>
</tr>
<tr>
<td>Cut-Off Standard</td>
<td>0.589 / 0.608</td>
<td>0.573 / 0.592</td>
<td>0.583</td>
</tr>
<tr>
<td>Weak Positive Control</td>
<td>0.866 / 0.874</td>
<td>0.850 / 0.858</td>
<td>0.854</td>
</tr>
<tr>
<td>Positive Control</td>
<td>1.951 / 1.920</td>
<td>1.935 / 1.904</td>
<td>1.920</td>
</tr>
</tbody>
</table>

The above table contains only an example, which was achieved under arbitrary temperature and environmental conditions. The described data constitute consequently no reference values which have to be found in each laboratory individually.

9.1. Qualitative Evaluation

The calculated absorptions for the patient sera, as mentioned above, are compared with the value for the cut-off standard. If the value of the sample is higher, there is a positive result.

For a value below the cut-off standard, there is a negative result. It seems reasonable to define a range of +/- 20 % around the value of the cut-off as a grey zone. In such a case the repetition of the test with the same serum or with a new sample of the same patient, taken after 2-4 weeks, is recommended. Both samples should be measured in parallel in the same run.

The positive control must show at least the double absorption compared with the cut-off standard.

9.2. Quantitative Evaluation

The ready-to-use standards and controls of the Parainfluenza 1, 2 & 3 antibody kit are defined and expressed in arbitrary units (U/mL). This results in an exact and reproducible quantitative evaluation. Consequently for a given patient follow-up controls become possible. The values for controls and standards in units are printed on the labels of the vials.

For a quantitative evaluation the absorptions of the standards and controls are graphically drawn against their concentrations. From the resulting reference curve the concentration values for each patient sample can then be extracted in relation to their absorptions. It is also possible to use automatic computer programs.
10. Assay Performance
The intra-assay coefficient of variation of the Parainfluenza 1, 2 & 3 IgM test kit was assessed by a ten-fold determination of a positive serum sample to less than 10%.

11. References

12. Ordering Information

<table>
<thead>
<tr>
<th>Country</th>
<th>Telephone</th>
<th>Facsimile</th>
<th>Address</th>
</tr>
</thead>
</table>
| Argentina | +54 1 502 7788 | +54 1 502 7788 | ICN Argentina  
Teodoro Vilardebo 2855-65  
(1417) Capital Federal |
| Australia | +61 2 9838 7422 | +61 2 9838 7390 | ICN Biomedicals Australasia Pty. Ltd.  
PO Box 187  
Unit 12, 167 Prospect Hwy.  
Seven Hills, NSW 2147 |
| Austria   | 00800 426 67337 | 00800 329 67337 | Please contact our German office directly. |
| Belgium   | +32 2 466 00 00  
1 800 249 999 | +32 2 466 26 42  
1 800 818 671 | ICN Biomedicals NV/SA  
Doornveld 10, B-1731 Asse-Relegem |
| Canada    | (800) 854 0530 | (800) 334 6999 | Please contact our USA office directly. |
| France    | +33 1 60 193 737  
0800 130 373 | +33 1 60 193 460  
0800 130 373 | ICN Pharmaceuticals France S.A.  
Division Biomedicals  
Parc Club D’Orsay, 24 Rue Jean Rostand,  
F-91893 Orsay Cedex |
| Germany   | +49 5651 921 0  
0800 426 67337 | +49 5651 921 181  
0800 629 67337 | ICN Biomedicals GmbH  
Thüringer Straße 15, D-37269 Eschwege |
<p>| Hungary   | +36 42 372 511/087 | +36 42 372 137 | ICN Hungary Company, Ltd. |</p>
<table>
<thead>
<tr>
<th>Country</th>
<th>Phone 1</th>
<th>Phone 2</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Italy</td>
<td>800-011 643</td>
<td>800-255 220</td>
<td>Kabay Janos u. 29, H-4440 Tiszavasvari PF1</td>
</tr>
<tr>
<td></td>
<td>ICN Pharmaceuticals, S.r.l. Divisione Biomedicale Centro Direzionale Milano 2, Palazzo Canova, I-20090 Segrate (MI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>+81 (03) 3808 2102</td>
<td>+81 (03) 3808 2401</td>
<td>ICN Pharmaceuticals, K.K. Pineland Bldg. 4F, 3-11 Nihonbashi Ohdenmacho Chuo-ku, Tokyo 103-0011</td>
</tr>
<tr>
<td>Mexico</td>
<td>+52 5 670 0739</td>
<td>+52 5 581 4938</td>
<td>ICN Farmaceutica, S.A. de C.V. Calzada Ermita Iztapalapa 436, Col. Mexicaltzingo, 09080 Mexico-DF</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>0800 022 74 16</td>
<td>0800 022 74 89</td>
<td>ICN Biomedicals BV Postbus 386, 2700 AJ Zoetermeer</td>
</tr>
<tr>
<td>Poland</td>
<td>+48 22 646 51 78</td>
<td>+48 22 651 20 35</td>
<td>ICN Polfa Rzeszów Biomedical Research Products Biuro Marketingu i Sprzedazy, Al. Szucha 13/15 00-580 Warszawa</td>
</tr>
<tr>
<td>Russia</td>
<td>+7 (095) 363 6611</td>
<td>+7 (095) 363 6611</td>
<td>ICN Pharmaceuticals, Inc. Usacheva, 24, Moscow 119048</td>
</tr>
<tr>
<td>Switzerland</td>
<td>00800 426 67337</td>
<td>00800 329 67337</td>
<td>Please contact the German office directly.</td>
</tr>
<tr>
<td>UK</td>
<td>+44 1256 374 620</td>
<td>+44 1256 374 621</td>
<td>ICN Pharmaceuticals Ltd. Cedarwood, Chineham Business Park</td>
</tr>
<tr>
<td></td>
<td>0800 282 474</td>
<td>0800 614 735</td>
<td>Crockford Lane, Basingstoke RG24 8WD</td>
</tr>
<tr>
<td>USA</td>
<td>+1 949 260 1032</td>
<td>+1 949 851 0563</td>
<td>ICN Diagnostics 16632 Millikan Ave. Irvine, CA 92606</td>
</tr>
<tr>
<td>Yugoslavia</td>
<td>+381 11 619 333</td>
<td>+381 11 199 424</td>
<td>ICN Yugoslavia Batajnicki drum bb, Belgrade, Zemun 11080</td>
</tr>
</tbody>
</table>